

Prevea360 Health Plan's Claims Payment Policies for Drugs & Biological Agents

Prevea360 has implemented claims processing logic surrounding a number of drug and biologic agents to ensure claims are processed consistently and in accordance with guidelines set forth by industry authorities.

The drugs affected by these policies include:

Omalizumab (Xolair®), Bevacizumab (Avastin®), Pegfilgrastim (Neulasta®), Filgrastim (Neupogen®), Paclitaxel (Taxol®), Paclitaxel protein-bound particles (Abraxane®), Doxorubicin HCL (Doxil®), Docetaxel (Taxotere®), Infliximab (Remicade®), Trastuzumab (Herceptin®), Antihemophilic Factor VIII, Antihemophilic Factor IX, Rituximab (Rituxan®), Iron Sucrose, Iron Dextran, Zoledronic Acid (Zometa®), Zoledronic Acid (Reclast®), Palonosetron HCl (Aloxi®), Ranibizumab (Lucentis®), Amphotericin B Liposome (AmBisome®), Oxaliplatin (Eloxatin®), Bortezomib (Velcade®), Leuprolide Acetate (Lupron®), Leuprolide Acetate Depot (Lupron Depot®, Eligard®), Leuprolide Acetate Implant, Cetuximab (Erbix®), Sodium Hyaluronate (Hyalagan®, Supartz®, Synvisc®, Euflexxa®, Orthovisc®), Darbepoetin Alfa (Aranesp®), Epoetin Alfa (Procrit®, Epogen®), Octreotide Acetate (Sandostatin LAR®), Velaglucerase Alfa, Alglucerase and Imiglucerase (VPRIV™, Cerezyme®, Ceredase®), Fulvestrant (Faslodex®)

Payment Policy Source

The primary source for these payment policies is the manufacturer's package insert (FDA approved indications). Other industry authority references include but are not limited to sources such as Elsevier Gold Standard's Clinical Pharmacology, Thomson MICROMEDEX® (DRUGDEX®, DrugPoints®), American Hospital Formulary System (AHFS) DI, National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, and Centers for Medicare and Medicaid Services (CMS) Regional Local Carrier Determinations (LCDs).

The new payment policies will enforce guidelines such as appropriate indications and frequency for use, dosing limits, etc. Specifically:

- The drug must be used for labeled or industry accepted off-labeled indications
- The dosage must be appropriate for the specific condition of the patient
- The frequency of administration must be appropriate for the diagnosis for which it is being used
- The drug must be appropriate for the age and gender of the patient to whom it is being administered
- The drug should not be given with other drugs that might cause an adverse reaction
- The drug should be administered by the appropriate route (i.e. injection, intravenous infusion, intralesional, intra-arterial, etc.)

Important Notes

- This policy will apply to professional and facility claims.

Please feel free to contact our Customer Care Center at 877-230-7555 should you have any questions.